Amendments to the Specification:

Please amend the specification as follows:

Please replace the paragraph beginning on page 8, line 19, and ending on page 9, line 3, with the following paragraph:

- - In an embodiment of the present invention, serum MIF levels are detected by immunoassays. Generally, immunoassays involve the binding of the MIF and anti-MIF antibody. The presence and amount of binding indicate the presence and amount of MIF present in the sample. Examples of immunoassays include, but are not limited to, protein arrays, ELISAs, radioimmunoassays, and immunoblots, which are well known in the art. The antibody can be polyclonal or monoclonal and is preferably labeled for easy detection. The labels can be, but are not limited to biotin, fluorescent molecules, radioactive molecules, chromogenic substrates, chemi-luminescence, and enzymes. - -

Please replace the paragraph beginning on page 6, line 18, and ending on page 7, line 3, with the following paragraph:

- - As described herein, the serum MIF may be used as diagnostic markers for the prediction or identification of prostate cancer. For instance, a serum sample from a patient may be assayed by any of the methods described herein or by any other method known to those skilled in the art, and the expression levels MIF may be compared to the expression levels found in normal serum. The serum expression levels of MIF that substantially resemble an expression level from the serum of normal or of diseased prostate may be used, for instance, to aid in disease diagnosis and/or prognosis. Comparison of the serum MIF levels may be done by researcher or

diagnostician or may be done with the aid of a computer and databases. Preferably, the present method involves comparing the levels of MIF in the serum of the individual to the MIF levels of prostate cancer patients. - -

Please replace the paragraph beginning on page 7, line 4, and ending on page 7, line 7, with the following paragraph:

- - Serum MIF levels of greater than about 5 to about 10 ng/ml, most preferably greater than about 6 ng/ml, indicates the presence of prostate cancer. Serum MIF levels can also be used in conjunction with the commonly ~~uses~~ used PSA test to accurately detect the presence of prostate cancer. - -